- Public Comps
- SynBiotic
SynBiotic Valuation Multiples
Discover SynBiotic's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like HYTN Innovations, Humanoid Global Holdings, Vitura Health, Weed and more.
SynBiotic Overview
About SynBiotic
SynBiotic SE is engaged in the development of Phyto-cannabinoids and other herbal compounds concentrated molecules as well as the development of wellness products. The company engages in synthetic production, drug development, cannabinoids, dietary supplements and cosmetic products. Geographical presence in Germany, Austria, UK, Switzerland and Other countries. Majority of its revenue comes from domestic market.
Founded
2015
HQ

Employees
103
Website
Financials (FY)
EV
$13M
Valuation Multiples
Start free trialSynBiotic Financials
SynBiotic reported last fiscal year revenue of $16M and negative EBITDA of ($2M).
In the same fiscal year, SynBiotic generated $6M in gross profit, ($2M) in EBITDA losses, and had net loss of ($11M).
Revenue (LTM)
SynBiotic P&L
In the most recent fiscal year, SynBiotic reported revenue of $16M and EBITDA of ($2M).
SynBiotic is unprofitable as of last fiscal year, with gross margin of 34%, EBITDA margin of (14%), and net margin of (68%).
Financial data powered by Morningstar, Inc.
SynBiotic Stock Performance
SynBiotic has current market cap of $9M, and enterprise value of $13M.
Market Cap Evolution
SynBiotic's stock price is $1.30.
SynBiotic share price decreased by 0.2% in the last 30 days, and by 53.5% in the last year.
SynBiotic has an EPS (earnings per share) of $-1.52.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13M | $9M | -0.1% | -0.2% | -33.8% | -53.5% | $-1.52 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSynBiotic Valuation Multiples
SynBiotic trades at 0.8x EV/Revenue multiple, and (5.6x) EV/EBITDA.
EV / Revenue (LTM)
SynBiotic Financial Valuation Multiples
As of July 14, 2026, SynBiotic has market cap of $9M and EV of $13M.
SynBiotic has a P/E ratio of (0.9x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SynBiotic Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


SynBiotic Margins & Growth Rates
SynBiotic decreased revenue by 22% and EBITDA by 65% in the last fiscal year.
In the most recent fiscal year, SynBiotic reported gross margin of 34%, EBITDA margin of (14%), and net margin of (68%).
SynBiotic Margins
SynBiotic Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
SynBiotic Operational KPIs
SynBiotic's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
SynBiotic Competitors
SynBiotic competitors include HYTN Innovations, Humanoid Global Holdings, Vitura Health, Weed, Peak Processing, Aion Therapeutic, Ayr Wellness, Dogecoin Cash, Neon Bloom and Pharmadrug.
Most SynBiotic public comparables operate across Cannabis, CannaTech and ViceTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 7.8x | - | (11.3x) | - | |||
| 946.9x | - | (6.0x) | - | |||
| 0.2x | - | 3.6x | - | |||
| - | - | (3.4x) | - | |||
| 1.8x | - | (9.0x) | - | |||
| 14.4x | - | (0.9x) | - | |||
| 1.3x | - | (3.9x) | - | |||
| 1.5x | - | (0.1x) | - | |||
This data is available for Pro users. Sign up to see all SynBiotic competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by SynBiotic
SynBiotic has acquired 2 companies to date.
Last acquisition by SynBiotic was on November 14th 2024. SynBiotic acquired WEECO Pharma for $13M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by SynBiotic
| Description | WEECO Pharma wholesales and imports medical cannabis products across Europe. The Berlin-based firm supplies raw materials, finished goods, and related services to pharmacies and clinics. It handles regulatory-compliant distribution for therapeutic cannabis applications. | Ilesol Pharmaceuticals is a Danish manufacturer of white-label CBD and CBG oils, capsules, and cosmetics compliant with EU novel food regulations. Its production facility in Denmark supplies bulk extracts and finished products to brands in Europe and North America. |
| HQ Country | ||
| HQ City | Hildesheim | Varaždin |
| Deal Date | 14 Nov 2024 | 19 Apr 2024 |
| Valuation | $13M | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all SynBiotic acquisitions and their M&A valuation multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SynBiotic
| When was SynBiotic founded? | SynBiotic was founded in 2015. |
| Where is SynBiotic headquartered? | SynBiotic is headquartered in Germany. |
| How many employees does SynBiotic have? | As of today, SynBiotic has over 103 employees. |
| Is SynBiotic publicly listed? | Yes, SynBiotic is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of SynBiotic? | SynBiotic trades under SBX ticker. |
| When did SynBiotic go public? | SynBiotic went public in 2021. |
| Who are competitors of SynBiotic? | SynBiotic main competitors include HYTN Innovations, Humanoid Global Holdings, Vitura Health, Weed, Peak Processing, Aion Therapeutic, Ayr Wellness, Dogecoin Cash, Neon Bloom, Pharmadrug. |
| What is the current market cap of SynBiotic? | SynBiotic's current market cap is $9M. |
| What is the current revenue of SynBiotic? | SynBiotic's last fiscal year revenue is $16M. |
| What is the current revenue growth of SynBiotic? | SynBiotic revenue growth (vs. last FY) is (22%). |
| What is the current EV/Revenue multiple of SynBiotic? | Current revenue multiple of SynBiotic is 0.8x. |
| Is SynBiotic profitable? | No, SynBiotic is not profitable. |
| How many companies SynBiotic has acquired to date? | As of July 2026, SynBiotic has acquired 2 companies. |
| What was the largest acquisition by SynBiotic? | $13M acquisition of WEECO Pharma on 14th November 2024 was the largest M&A SynBiotic has done to date. |
| What companies SynBiotic acquired? | SynBiotic acquired WEECO Pharma and Ilesol Pharmaceuticals. |
| In how many companies SynBiotic has invested to date? | SynBiotic hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to SynBiotic
Lists including SynBiotic
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.






